IL17A and metabolic dysfunction-associated steatohepatitis: Interventions targeting IL-17 or its signaling through pharmacological inhibitors, neutralizing antibodies or genetic deletion (Il17a-/- or Il17ra-/-), effectively decreased inflammation in several MASH models by reducing hepatocyte injury, the infiltration of pro-inflammatory immune cells, and the release of chemokines and cytokines (131–133, 145–147, 156).